Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Find out more about the MS-UK Helpline

Find out more about our Choices booklets

Find out more about New Pathways magazine

 


A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a...
A group of T2 weighted hyperintensities that disseminate in what is called a “punctate pattern” (PP) may directly precede the appearance of progressive multifocal leukoencephalopathy (PML) lesions,...
A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with Tecfidera has raised questions of whether the drug reactivates the...
Secondary health issues are very common in multiple sclerosis (MS) and exerts a significant impact on health-related quality of life (HRQoL), results of two studies published in Neurology indicate....
Three in five people who contest a decision to reject their Personal Independence Payment win on appeal, figures have revealed. Huge numbers of disabled people are being wrongly denied Personal...
The immune system-suppressing multiple sclerosis (MS) drug Gilenya also has potentially beneficial effects on the nervous system, according to a recent study. Gilenya is a relatively new medication...
Yoga and aquatic exercise may reduce certain symptoms of multiple sclerosis (MS) such as fatigue, depression and paraesthesia, a new study suggests. For the study, researchers from University of...
PJSC Pharmsynthez, a pharmaceutical company based in Russia, has announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its therapeutic vaccine...
Recent studies have shown that Tecfidera decreased certain immune cells, of both B-, and T-cell type in MS patients. Studies have also indicated that this class of drugs affects the signalling...
RedHill Biopharma has announced “encouraging” top-line interim results from its CEASE-MS Phase IIa proof-of-concept (PoC) clinical study evaluating fixed oral doses of RHB-104 in patients treated for...

Pages